source
- Silence causes uproar in rare blood cancer space as data sets high bar for competitorsThe mid-stage win of Silence Therapeutics’ siRNA drug in polycythemia vera validates the therapeutic approach of similar assets in development—but also sets a high standard for therapies from Taked…
- FDA rejects ITM radiopharma therapy while WHO defends immunization schedulesThe U.S. Food and Drug Administration has issued a rejection of a radiopharmaceutical therapy identified as ITM, indicating that the product did not meet the agency's requirements for approval. Th…